OPRM1 SNP (A118G): Involvement in disease development, treatment response, and animal models

Drug and Alcohol Dependence

Volumn 108, Issue 3, 2010, Pages 172-182

  Mague, Stephen D ^a   Blendy, Julie A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alcohol; Analgesia; Dependence; Morphine; Pain; Stress

Indexed keywords

ALFENTANIL; CYSTEINE; FENTANYL; GUANINE; METHADONE; METHAMPHETAMINE; MORPHINE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; NALTREXONE; OPIATE; OXYCODONE;

ALCOHOLISM; AMINO ACID SUBSTITUTION; ANALGESIA; CANCER PAIN; CHRONIC PAIN; DRUG MECHANISM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HEROIN DEPENDENCE; HETEROZYGOTE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KNOCKOUT MOUSE; NONHUMAN; PAIN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN FUNCTION; RESPIRATION DEPRESSION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TOBACCO DEPENDENCE;

ANALGESICS, OPIOID; ANIMALS; DISEASE MODELS, ANIMAL; GENETIC VARIATION; HUMANS; OPIOID-RELATED DISORDERS; PAIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; TREATMENT OUTCOME;

ANIMALIA; MUS;

EID: 77952420724     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.12.016     Document Type: Review

References (134)

1. Anton R.F., Oroszi G., O'Malley S., Couper D., Swift R., Pettinati H., Goldman D. An evaluation of mu-opioid receptor (Oprm1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for Alcohol Dependence (Combine) Study. Arch. Gen. Psychiatry 2008, 65:135-144.
2. Arias A., Feinn R., Kranzler H.R. Association of an Asn40asp (A118g) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 2006, 83:262-268.
3. Arias A.J., Armeli S., Gelernter J., Covault J., Kallio A., Karhuvaara S., Koivisto T., Makela R., Kranzler H.R. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin. Exp. Res. 2008, 32:1159-1166.
4. Barr C.S., Chen S.A., Schwandt M.L., Lindell S.G., Sun H., Suomi S.J., Heilig M. Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the mu-opioid receptor gene locus. Biol. Psychiatry 2010, 67:78-80.
5. Barr C.S., Schwandt M., Lindell S.G., Chen S.A., Goldman D., Suomi S.J., Higley J.D., Heilig M. Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Arch. Gen. Psychiatry 2007, 64:369-376.
6. Barr C.S., Schwandt M.L., Lindell S.G., Higley J.D., Maestripieri D., Goldman D., Suomi S.J., Heilig M. Variation at the mu-opioid receptor gene (Oprm1) influences attachment behavior in infant primates. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:5277-5281.
7. Bart G., Heilig M., LaForge K.S., Pollak L., Leal S.M., Ott J., Kreek M.J. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol. Psychiatry 2004, 9:547-549.
8. Bart G., Kreek M.J., Ott J., LaForge K.S., Proudnikov D., Pollak L., Heilig M. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 2005, 30:417-422.
9. Bart G., LaForge K.S., Borg L., Lilly C., Ho A., Kreek M.J. Altered levels of basal cortisol in healthy subjects with a 118g allele in exon 1 of the mu opioid receptor gene. Neuropsychopharmacology 2006, 31:2313-2317.
10. Bayerer B., Stamer U., Hoeft A., Stuber F. Genomic variations and transcriptional regulation of the human mu-opioid receptor gene. Eur. J. Pain 2007, 11:421-427.
11. Befort K., Filliol D., Decaillot F.M., Gaveriaux-Ruff C., Hoehe M.R., Kieffer B.L. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J. Biol. Chem. 2001, 276:3130-3137.
12. Bergen A.W., Kokoszka J., Peterson R., Long J.C., Virkkunen M., Linnoila M., Goldman D. Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol. Psychiatry 1997, 2:490-494.
13. Berrendero F., Kieffer B.L., Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J. Neurosci. 2002, 22:10935-10940.
14. Berrettini W.H., Hoehe M.R., Ferraro T.N., DeMaria P.A., Gottheil E. Human mu opiod receptor gene polymorphisms and vulnerability to substance abuse. Addict. Biol. 1997, 2:303-308.
15. Beyer A., Koch T., Schroder H., Schulz S., Hollt V. Effect of the A118g polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J. Neurochem. 2004, 89:553-560.
16. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., Gong J., Schluger J., Strong J.A., Leal S.M., Tischfield J.A., Kreek M.J., Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:9608-9613.
17. Campa D., Gioia A., Tomei A., Poli P., Barale R. Association of Abcb1/Mdr1 and Oprm1 gene polymorphisms with morphine pain relief. Clin. Pharmacol. Ther. 2008, 83:559-566.
18. Chiu C.T., Ma T., Ho I.K. Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone. Brain Res. Bull. 2005, 67:100-109.
19. Chong R.Y., Oswald L., Yang X., Uhart M., Lin P.I., Wand G.S. The micro-opioid receptor polymorphism A118g predicts cortisol responses to naloxone and stress. Neuropsychopharmacology 2006, 31:204-211.
20. Chou W.Y., Wang C.H., Liu P.H., Liu C.C., Tseng C.C., Jawan B. Human opioid receptor A118g polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006, 105:334-337.
21. Chou W.Y., Yang L.C., Lu H.F., Ko J.Y., Wang C.H., Lin S.H., Lee T.H., Concejero A., Hsu C.J. Association of mu-opioid receptor gene polymorphism (A118g) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol. Scand. 2006, 50:787-792.
22. Coulbault L., Beaussier M., Verstuyft C., Weickmans H., Dubert L., Tregouet D., Descot C., Parc Y., Lienhart A., Jaillon P., Becquemont L. Environmental and genetic factors associated with morphine response in the postoperative period. Clin. Pharmacol. Ther. 2006, 79:316-324.
23. Crowley J.J., Oslin D.W., Patkar A.A., Gottheil E., DeMaria P.A., O'Brien C.P., Berrettini W.H., Grice D.E. A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr. Genet. 2003, 13:169-173.
24. Davenport K.E., Houdi A.A., Van Loon G.R. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci. Lett. 1990, 113:40-46.
25. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:5274-5278.
26. Dick D.M., Foroud T. Candidate genes for alcohol dependence: a review of genetic evidence from human studies. Alcohol Clin. Exp. Res. 2003, 27:868-879.
27. Drakenberg K., Nikoshkov A., Horvath M.C., Fagergren P., Gharibyan A., Saarelainen K., Rahman S., Nylander I., Bakalkin G., Rajs J., Keller E., Hurd Y.L. Mu opioid receptor A118g polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:7883-7888.
28. Du Y., Wan Y.J. The interaction of reward genes with environmental factors in contribution to alcoholism in Mexican Americans. Alcohol Clin. Exp. Res. 2009.
29. Eisenberger N.I., Lieberman M.D. Why rejection hurts: a common neural alarm system for physical and social pain. Trends Cognit. Sci. 2004, 8:294-300.
30. Enoch M.A. Pharmacogenomics of alcohol response and addiction. Am. J. Pharmacogenomics 2003, 3:217-232.
31. 2+ receptor is essential for its expression at the cell surface. Endocrinology 1997, 138:1916-1922.
32. Filbey F.M., Ray L., Smolen A., Claus E.D., Audette A., Hutchison K.E. Differential neural response to alcohol priming and alcohol taste cues is associated with Drd4 Vntr and Oprm1 genotypes. Alcohol Clin. Exp. Res. 2008, 32:1113-1123.
33. Fillingim R.B., Kaplan L., Staud R., Ness T.J., Glover T.L., Campbell C.M., Mogil J.S., Wallace M.R. The A118g single nucleotide polymorphism of the mu-opioid receptor gene (Oprm1) is associated with pressure pain sensitivity in humans. J. Pain 2005, 6:159-167.
34. Franke P., Wang T., Nothen M.M., Knapp M., Neidt H., Albrecht S., Jahnes E., Propping P., Maier W. Nonreplication of association between mu-opioid-receptor gene (Oprm1) A118g polymorphism and substance dependence. Am. J. Med. Genet. 2001, 105:114-119.
35. Gelernter J., Gueorguieva R., Kranzler H.R., Zhang H., Cramer J., Rosenheck R., Krystal J.H. Opioid receptor gene (Oprm1, Oprk1, and Oprd1) variants and response to naltrexone treatment for alcohol dependence: results from the Va cooperative study. Alcohol Clin. Exp. Res. 2007, 31:555-563.
36. Gelernter J., Kranzler H., Cubells J. Genetics of two mu opioid receptor gene (Oprm1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol. Psychiatry 1999, 4:476-483.
37. Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr. Top. Med. Chem. 2004, 4:39-50.
38. Gianoulakis C., Barcomb A. Effect of acute ethanol in vivo and in vitro on the beta-endorphin system in the rat. Life Sci. 1987, 40:19-28.
39. Glatt S.J., Bousman C., Wang R.S., Murthy K.K., Rana B.K., Lasky-Su J.A., Zhu S.C., Zhang R., Li J., Zhang B., Li J., Lyons M.J., Faraone S.V., Tsuang M.T. Evaluation of Oprm1 variants in heroin dependence by family-based association testing and meta-analysis. Drug Alcohol Depend. 2007, 90:159-165.
40. Gscheidel N., Sander T., Wendel B., Heere P., Schmidt L.G., Rommelspacher H., Hoehe M.R., Samochowiec J. Five exon 1 variants of mu opioid receptor and vulnerability to alcohol dependence. Pol. J. Pharmacol. 2000, 52:27-31.
41. Haile C.N., Kosten T.A., Kosten T.R. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am. J. Drug Alcohol Abuse 2008, 34:355-381.
42. Hall F.S., Sora I., Uhl G.R. Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology (Berl.) 2001, 154:43-49.
43. Hayashida M., Nagashima M., Satoh Y., Katoh R., Tagami M., Ide S., Kasai S., Nishizawa D., Ogai Y., Hasegawa J., Komatsu H., Sora I., Fukuda K., Koga H., Hanaoka K., Ikeda K. Analgesic requirements after major abdominal surgery are associated with oprm1 gene polymorphism genotype and haplotype. Pharmacogenomics 2008, 9:1605-1616.
44. Hernandez-Avila C.A., Covault J., Wand G., Zhang H., Gelernter J., Kranzler H.R. Population-specific effects of the Asn40asp polymorphism at the mu-opioid receptor gene (Oprm1) on Hpa-axis activation. Pharmacogenet. Genomics 2007, 17:1031-1038.
45. Hernandez-Avila C.A., Wand G., Luo X., Gelernter J., Kranzler H.R. Association between the cortisol response to opioid blockade and the Asn40asp polymorphism at the mu-opioid receptor locus (Oprm1). Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2003, 118B:60-65.
46. Ide S., Kobayashi H., Tanaka K., Ujike H., Sekine Y., Ozaki N., Inada T., Harano M., Komiyama T., Yamada M., Iyo M., Ikeda K., Sora I. Gene polymorphisms of the mu opioid receptor in methamphetamine abusers. Ann. N.Y. Acad. Sci. 2004, 1025:316-324.
47. Ide S., Kobayashi H., Ujike H., Ozaki N., Sekine Y., Inada T., Harano M., Komiyama T., Yamada M., Iyo M., Iwata N., Tanaka K., Shen H., Iwahashi K., Itokawa M., Minami M., Satoh M., Ikeda K., Sora I. Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms. Pharmacogenomics J. 2006, 6:179-188.
48. Janicki P.K., Schuler G., Francis D., Bohr A., Gordin V., Jarzembowski T., Ruiz-Velasco V., Mets B. A genetic association study of the functional A118g polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. Anesth. Analg. 2006, 103:1011-1017.
49. Johnson A.D., Zhang Y., Papp A.C., Pinsonneault J.K., Lim J.E., Saffen D., Dai Z., Wang D., Sadee W. Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet. Genomics 2008, 18:781-791.
50. Johnson S.W., North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 1992, 12:483-488.
51. Kalivas P.W., McFarland K. Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology (Berl.) 2003, 168:44-56.
52. Kapur S., Sharad S., Singh R.A., Gupta A.K. A118g polymorphism in mu opioid receptor gene (Oprm1): association with opiate addiction in subjects of Indian origin. J. Integr. Neurosci. 2007, 6:511-522.
53. Kim S.A., Kim J.W., Song J.Y., Park S., Lee H.J., Chung J.H. Association of polymorphisms in nicotinic acetylcholine receptor alpha 4 subunit gene (Chrna4), mu-opioid receptor gene (Oprm1), and ethanol-metabolizing enzyme genes with alcoholism in Korean patients. Alcohol 2004, 34:115-120.
54. Kim S.G., Kim C.M., Choi S.W., Jae Y.M., Lee H.G., Son B.K., Kim J.G., Choi Y.S., Kim H.O., Kim S.Y., Oslin D.W. A micro opioid receptor gene polymorphism (A118g) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl.) 2009, 201:611-618.
55. Kim S.G., Kim C.M., Kang D.H., Kim Y.J., Byun W.T., Kim S.Y., Park J.M., Kim M.J., Oslin D.W. Association of functional opioid receptor genotypes with alcohol dependence in Koreans. Alcohol Clin. Exp. Res. 2004, 28:986-990.
56. Klepstad P., Rakvag T.T., Kaasa S., Holthe M., Dale O., Borchgrevink P.C., Baar C., Vikan T., Krokan H.E., Skorpen F. The 118 a>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. 2004, 48:1232-1239.
57. Koch T., Kroslak T., Averbeck M., Mayer P., Schroder H., Raulf E., Hollt V. Allelic variation S268p of the human mu-opioid receptor affects both desensitization and G protein coupling. Mol. Pharmacol. 2000, 58:328-334.
58. Kosarac B., Fox A.A., Collard C.D. Effect of genetic factors on opioid action. Curr. Opin. Anaesthesiol. 2009.
59. Kranzler H.R., Gelernter J., O'Malley S., Hernandez-Avila C.A., Kaufman D. Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (Oprm1). Alcohol Clin. Exp. Res. 1998, 22:1359-1362.
60. Kreek M.J., Koob G.F. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 1998, 51:23-47.
61. Kreek M.J., LaForge K.S. Stress responsivity, addiction, and a functional variant of the human mu-opioid receptor gene. Mol Interv. 2007, 7:74-78.
62. Kroslak T., Laforge K.S., Gianotti R.J., Ho A., Nielsen D.A., Kreek M.J. The single nucleotide polymorphism A118g alters functional properties of the human mu opioid receptor. J. Neurochem. 2007, 103:77-87.
63. LaForge K.S., Yuferov V., Kreek M.J. Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur. J. Pharmacol. 2000, 410:249-268.
64. Landau R., Kern C., Columb M.O., Smiley R.M., Blouin J.L. Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain 2008, 139:5-14.
65. Lerman C., Wileyto E.P., Patterson F., Rukstalis M., Audrain-McGovern J., Restine S., Shields P.G., Kaufmann V., Redden D., Benowitz N., Berrettini W.H. The functional mu opioid receptor (Oprm1) Asn40asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J. 2004, 4:184-192.
66. Loh el W., Fann C.S., Chang Y.T., Chang C.J., Cheng A.T. Endogenous opioid receptor genes and alcohol dependence among Taiwanese Han. Alcohol Clin. Exp. Res. 2004, 28:15-19.
67. Lotsch J., Skarke C., Grosch S., Darimont J., Schmidt H., Geisslinger G. The polymorphism A118g of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002, 12:3-9.
68. Lotsch J., Skarke C., Liefhold J., Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin. Pharmacokinet. 2004, 43:983-1013.
69. Luo X., Kranzler H.R., Zhao H., Gelernter J. Haplotypes at the Oprm1 locus are associated with susceptibility to substance dependence in European-Americans. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2003, 120B:97-108.
70. Mague S.D., Isiegas C., Huang P., Liu-Chen L.Y., Lerman C., Blendy J.A. Mouse model of Oprm1 (A118g) polymorphism has sex-specific effects on drug-mediated behavior. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:10847-10852.
71. Mantione K.J., Goumon Y., Esch T., Stefano G.B. Morphine 6beta glucuronide: fortuitous morphine metabolite or preferred peripheral regulatory opiate?. Med. Sci. Monit. 2005, 11:MS43-46.
72. 2+ channels by heterologously expressed wild-type and mutant human micro-opioid receptors (Hmors) containing the A118g single-nucleotide polymorphism. J. Neurophysiol. 2007, 97:1058-1067.
73. McGeary J.E., Monti P.M., Rohsenow D.J., Tidey J., Swift R., Miranda R. Genetic moderators of Naltrexone's effects on alcohol cue reactivity. Alcohol Clin. Exp. Res. 2006, 30:1288-1296.
74. Miller G.M., Bendor J., Tiefenbacher S., Yang H., Novak M.A., Madras B.K. A mu-opioid receptor single nucleotide polymorphism in rhesus monkey: association with stress response and aggression. Mol. Psychiatry 2004, 9:99-108.
75. Miranda R., Ray L., Justus A., Meyerson L.A., Knopik V.S., McGeary J., Monti P.M. Initial evidence of an association between Oprm1 and adolescent alcohol misuse. Alcohol Clin. Exp. Res. 2010, 34:112-122.
76. Munafo M.R., Elliot K.M., Murphy M.F., Walton R.T., Johnstone E.C. Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenomics J. 2007, 7:353-361.
77. Nestler E.J. Is there a common molecular pathway for addiction?. Nat. Neurosci. 2005, 8:1445-1449.
78. Nishizawa D., Han W., Hasegawa J., Ishida T., Numata Y., Sato T., Kawai A., Ikeda K. Association of mu-opioid receptor gene polymorphism A118g with alcohol dependence in a Japanese population. Neuropsychobiology 2006, 53:137-141.
79. O'Malley S.S., Jaffe A.J., Chang G., Schottenfeld R.S., Meyer R.E., Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch. Gen. Psychiatry 1992, 49:881-887.
80. Oertel B.G., Kettner M., Scholich K., Renne C., Roskam B., Geisslinger G., Schmidt P.H., Lotsch J. A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J. Biol. Chem. 2009, 284:6530-6535.
81. Oertel B.G., Schmidt R., Schneider A., Geisslinger G., Lotsch J. The mu-opioid receptor gene polymorphism 118a>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet. Genomics 2006, 16:625-636.
82. Oroszi G., Anton R.F., O'Malley S., Swift R., Pettinati H., Couper D., Yuan Q., Goldman D. Oprm1 Asn40asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin. Exp. Res. 2009, 33:383-393.
83. Oroszi G., Goldman D. Alcoholism: genes and mechanisms. Pharmacogenomics 2004, 5:1037-1048.
84. Oslin D.W., Berrettini W., Kranzler H.R., Pettinati H., Gelernter J., Volpicelli J.R., O'Brien C.P. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003, 28:1546-1552.
85. Oslin D.W., Berrettini W.H., O'Brien C.P. Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. Addict. Biol. 2006, 11:397-403.
86. Oswald L.M., Wand G.S. Opioids and alcoholism. Physiol. Behav. 2004, 81:339-358.
87. Pang G.S., Wang J., Wang Z., Goh C., Lee C.G. The G allele of Snp E1/A118g at the micro-opioid receptor gene locus shows genomic evidence of recent positive selection. Pharmacogenomics 2009, 10:1101-1109.
88. Perkins K.A., Lerman C., Grottenthaler A., Ciccocioppo M.M., Milanak M., Conklin C.A., Bergen A.W., Benowitz N.L. Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behav. Pharmacol. 2008, 19:641-649.
89. Pomerleau O.F. Endogenous opioids and smoking: a review of progress and problems. Psychoneuroendocrinology 1998, 23:115-130.
90. Pratt W.M., Davidson D. Role of the Hpa axis and the A118g polymorphism of the mu-opioid receptor in stress-induced drinking behavior. Alcohol Alcohol 2009, 44:358-365.
91. Rasmussen D.D., Bryant C.A., Boldt B.M., Colasurdo E.A., Levin N., Wilkinson C.W. Acute alcohol effects on opiomelanocortinergic regulation. Alcohol Clin. Exp. Res. 1998, 22:789-801.
92. Rathz D.A., Brown K.M., Kramer L.A., Liggett S.B. Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J. Cardiovasc. Pharmacol. 2002, 39:155-160.
93. Ray L.A., Hutchison K.E. A polymorphism of the mu-opioid receptor gene (Oprm1) and sensitivity to the effects of alcohol in humans. Alcohol Clin. Exp. Res. 2004, 28:1789-1795.
94. Ray L.A., Hutchison K.E. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch. Gen. Psychiatry 2007, 64:1069-1077.
95. Ray R., Jepson C., Patterson F., Strasser A., Rukstalis M., Perkins K., Lynch K.G., O'Malley S., Berrettini W.H., Lerman C. Association of Oprm1 A118g variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl.) 2006, 188:355-363.
96. Raynor K., Kong H., Chen Y., Yasuda K., Yu L., Bell G.I., Reisine T. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol. Pharmacol. 1994, 45:330-334.
97. Reid L.D., Czirr S.A., Milano W.C., Hubbell C.L., Manha N.A. Opioids and intake of alcoholic beverages. NIDA Res. Monogr. 1986, 75:359-362.
98. Reyes-Gibby C.C., Shete S., Rakvag T., Bhat S.V., Skorpen F., Bruera E., Kaasa S., Klepstad P. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: Oprm1 and Comt gene. Pain 2007, 130:25-30.
99. Roberts A.J., McDonald J.S., Heyser C.J., Kieffer B.L., Matthes H.W., Koob G.F., Gold L.H. Mu-opioid receptor knockout mice do not self-administer alcohol. J. Pharmacol. Exp. Ther. 2000, 293:1002-1008.
100. Romberg R.R., Olofsen E., Bijl H., Taschner P.E., Teppema L.J., Sarton E.Y., van Kleef J.W., Dahan A. Polymorphism of mu-opioid receptor gene (Oprm1:C.118a>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 2005, 102:522-530.
101. Rommelspacher H., Smolka M., Schmidt L.G., Samochowiec J., Hoehe M.R. Genetic analysis of the mu-opioid receptor in alcohol-dependent individuals. Alcohol 2001, 24:129-135.
102. Sander T., Gscheidel N., Wendel B., Samochowiec J., Smolka M., Rommelspacher H., Schmidt L.G., Hoehe M.R. Human mu-opioid receptor variation and alcohol dependence. Alcohol Clin. Exp. Res. 1998, 22:2108-2110.
103. Schinka J.A., Town T., Abdullah L., Crawford F.C., Ordorica P.I., Francis E., Hughes P., Graves A.B., Mortimer J.A., Mullan M. A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. Mol. Psychiatry 2002, 7:224-228.
104. Shabalina S.A., Zaykin D.V., Gris P., Ogurtsov A.Y., Gauthier J., Shibata K., Tchivileva I.E., Belfer I., Mishra B., Kiselycznyk C., Wallace M.R., Staud R., Spiridonov N.A., Max M.B., Goldman D., Fillingim R.B., Maixner W., Diatchenko L. Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum. Mol. Genet. 2009, 18:1037-1051.
105. Shi J., Hui L., Xu Y., Wang F., Huang W., Hu G. Sequence variations in the mu-opioid receptor gene (Oprm1) associated with human addiction to heroin. Hum. Mutat. 2002, 19:459-460.
106. Sia A.T., Lim Y., Lim E.C., Goh R.W., Law H.Y., Landau R., Teo Y.Y., Tan E.C. A118g single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 2008, 109:520-526.
107. Skorpen F., Laugsand E.A., Klepstad P., Kaasa S. Variable response to opioid treatment: any genetic predictors within sight?. Palliat. Med. 2008, 22:310-327.
108. Smolka M., Sander T., Schmidt L.G., Samochowiec J., Rommelspacher H., Gscheidel N., Wendel B., Hoehe M.R. Mu-opioid receptor variants and dopaminergic sensitivity in alcohol withdrawal. Psychoneuroendocrinology 1999, 24:629-638.
109. Sora I., Takahashi N., Funada M., Ujike H., Revay R.S., Donovan D.M., Miner L.L., Uhl G.R. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:1544-1549.
110. Sullivan P.F., Neale B.M., van den Oord E., Miles M.F., Neale M.C., Bulik C.M., Joyce P.R., Straub R.E., Kendler K.S. Candidate genes for nicotine dependence via linkage, epistasis, and bioinformatics. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2004, 126B:23-36.
111. Szeto C.Y., Tang N.L., Lee D.T., Stadlin A. Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts. Neuroreport 2001, 12:1103-1106.
112. Tan E.C., Lim E.C., Teo Y.Y., Lim Y., Law H.Y., Sia A.T. Ethnicity and Oprm variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. Mol. Pain 2009, 5:32.
113. Tan E.C., Tan C.H., Karupathivan U., Yap E.P. Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport 2003, 14:569-572.
114. Tidey J.W., Monti P.M., Rohsenow D.J., Gwaltney C.J., Miranda R., McGeary J.E., MacKillop J., Swift R.M., Abrams D.B., Shiffman S., Paty J.A. Moderators of Naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin. Exp. Res. 2008, 32:58-66.
115. Town T., Abdullah L., Crawford F., Schinka J., Ordorica P.I., Francis E., Hughes P., Duara R., Mullan M. Association of a functional mu-opioid receptor allele (+118a) with alcohol dependency. Am. J. Med. Genet. 1999, 88:458-461.
116. Vaccarino A.L., Kastin A.J. Endogenous opiates: 1999. Peptides 2000, 21:1975-2034.
117. Vallender E.J., Priddy C.M., Chen G.L., Miller G.M. Human expression variation in the mu-opioid receptor is paralleled in Rhesus Macaque. Behav. Genet. 2008, 38:390-395.
118. van den Wildenberg E., Wiers R.W., Dessers J., Janssen R.G., Lambrichs E.H., Smeets H.J., van Breukelen G.J. A functional polymorphism of the mu-opioid receptor gene (Oprm1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin. Exp. Res. 2007, 31:1-10.
119. van der Zwaluw C.S., van den Wildenberg E., Wiers R.W., Franke B., Buitelaar J., Scholte R.H., Engels R.C. Polymorphisms in the mu-opioid receptor gene (Oprm1) and the implications for alcohol dependence in humans. Pharmacogenomics 2007, 8:1427-1436.
120. Vink J.M., Beem A.L., Posthuma D., Neale M.C., Willemsen G., Kendler K.S., Slagboom P.E., Boomsma D.I. Linkage analysis of smoking initiation and quantity in Dutch sibling pairs. Pharmacogenomics J. 2004, 4:274-282.
121. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 1992, 49:876-880.
122. Walters C.L., Cleck J.N., Kuo Y.C., Blendy J.A. Mu-opioid receptor and Creb activation are required for nicotine reward. Neuron 2005, 46:933-943.
123. Wang D., Quillan J.M., Winans K., Lucas J.L., Sadee W. Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. J. Biol. Chem. 2001, 276:34624-34630.
124. Wang Z., Ray R., Faith M., Tang K., Wileyto E.P., Detre J.A., Lerman C. Nicotine abstinence-induced cerebral blood flow changes by genotype. Neurosci. Lett. 2008, 438:275-280.
125. Way B.M., Taylor S.E., Eisenberger N.I. Variation in the micro-opioid receptor gene (Oprm1) is associated with dispositional and neural sensitivity to social rejection. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:15079-15084.
126. Wiers R.W., Rinck M., Dictus M., van den Wildenberg E. Relatively strong automatic appetitive action-tendencies in male carriers of the Oprm1 G-allele. Genes Brain Behav. 2009, 8:101-106.
127. Wise R.A., Bozarth M.A. Brain mechanisms of drug reward and euphoria. Psychiatr. Med. 1985, 3:445-460.
128. Xuei X., Flury-Wetherill L., Bierut L., Dick D., Nurnberger J., Foroud T., Edenberg H.J. The opioid system in alcohol and drug dependence: family-based association study. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2007, 144B:877-884.
129. Zadina J.E., Hackler L., Ge L.J., Kastin A.J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997, 386:499-502.
130. Zhang D., Shao C., Shao M., Yan P., Wang Y., Liu Y., Liu W., Lin T., Xie Y., Zhao Y., Lu D., Li Y., Jin L. Effect of mu-opioid receptor gene polymorphisms on heroin-induced subjective responses in a Chinese population. Biol. Psychiatry 2007, 61:1244-1251.
131. Zhang H., Luo X., Kranzler H.R., Lappalainen J., Yang B.Z., Krupitsky E., Zvartau E., Gelernter J. Association between two mu-opioid receptor gene (Oprm1) haplotype blocks and drug or alcohol dependence. Hum. Mol. Genet. 2006, 15:807-819.
132. Zhang L., Kendler K.S., Chen X. The mu-opioid receptor gene and smoking initiation and nicotine dependence. Behav. Brain Funct. 2006, 2:28.
133. Zhang Y., Wang D., Johnson A.D., Papp A.C., Sadee W. Allelic expression imbalance of human mu opioid receptor (Oprm1) caused by variant A118g. J. Biol. Chem. 2005, 280:32618-32624.
134. Zhang Z., Austin S.C., Smyth E.M. Glycosylation of the human prostacyclin receptor: role in ligand binding and signal transduction. Mol. Pharmacol. 2001, 60:480-487.